Item 7.01 Regulation FD Disclosure. On September 14, 2026, Q32 Bio Inc. (the ”Company“) issued a press release announcing the appointment of José Trevejo, M.D., Ph. D., as the Company’s Chief Medical Officer and Ellie Hershberger, Pharm. D., as the Company’s Chief Development Officer. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On September 14, 2026, Q32 Bio Inc. (the ”Company“) issued a press release announcing the appointment of José Trevejo, M.D., Ph. D., as the Company’s Chief Medical Officer and Ellie Hershberger, Pharm. D., as the Company’s Chief Development Officer. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth under Item 7.01 (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On September 14, 2026, the Company announced the appointment of José Trevejo, M.D., Ph. D., as its Chief Medical Officer. Prior to joining the Company, Dr. Trevejo served as Chief Medical Officer and Head of Clinical Pipeline Strategy at Enveda Therapeutics, Inc. (“Enveda”), an AI-enabled drug discovery company, where he helped advance multiple clinical-stage candidates, including a Phase 2 candidate for atopic dermatitis, from July 2024 to September 2026. Prior to Enveda, Dr. Trevejo was Chief Medical Officer at Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) from February 2022 to February 2024, where he helped lead the FDA approval and successful launch of XDEMVY®, the first FDA-approved treatment for Demodex blepharitis. Before that, he served as Chief Development Officer at Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) from October 2020 to February 2022, a biotechnology company advancing genetic medicines for rare diseases. Dr. Trevejo received his M.D. and Ph. D. from the Cornell-Rockefeller-Sloan Kettering Tri-Institutional M.D.-Ph. D. Program and completed his residency and specialty training at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center, both Harvard Medical School affiliates.
Also on September 14, 2026, the Company announced the appointment of Ellie Hershberger, Pharm. D. as its Chief Development Officer. Prior to joining the Company, Dr. Hershberger was a consultant at EMH Consulting LLC from January 2023 to September 2026. Previously, she served as Chief Development Officer of Adagio Therapeutics, Inc. (“Adagio”), now Invivyd, Inc. (Nasdaq: IVVD) from June 2020 to January 2023, where she led the development organization and advanced the company’s lead monoclonal antibody candidate from IND-enabling activities through Phase 3 clinical development. As a member of the executive team, she also helped build the development infrastructure to support global approval and contributed to the company’s successful initial public offering. Following the completion of her Pharm. D. degree at Ferris State University, Dr. Hershberger completed a Research Fellowship in pharmacokinetics and pharmacodynamics at Wayne State University.
Filed exhibits (1)
EX-99.1 (by filename) d158730dex991.htm
EX-99.1
2
d158730dex991.htm
EX-99.1
EX-99.1
Exhibit 99.1
Q32 Bio Appoints José Trevejo, M.D., Ph. D., as Chief Medical Officer and Ellie Hershberger,
Pharm. D., as Chief Development Officer
- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20
years of experience spanning dermatology and late-stage clinical development -
- Dr. Hershberger is a drug
development leader with over 30 years of experience spanning late-stage development operations and regulatory
strategy -
WALTHAM, Mass., September 14, 2026 - Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio”), a clinical-stage
biotechnology company focused on developing innovative therapies for alopecia areata (“AA”) and other autoimmune and inflammatory diseases, today announced the appointment of José Trevejo, M.D., Ph. D., as Chief Medical
Officer and Ellie Hershberger, Pharm. D., as Chief Development Officer.
“José and Ellie join Q32 Bio at a pivotal moment as we transition
into a late clinical stage company in line with our preparations to advance bempikibart into a registration-directed program for severe or very severe alopecia areata and continue to evaluate expansion opportunities in additional alopecia…
